Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Medpace Holdings, Inc. (Nasdaq: MEDP), a scientifically driven, global, full-service clinical contract research organization (CRO). Through these filings, investors can review the company’s official financial statements, risk disclosures, material agreements and other regulatory information that frame analysis of MEDP stock.
Medpace’s SEC reporting includes annual reports on Form 10-K, which contain audited financial statements, management’s discussion and analysis, and a detailed “Risk Factors” section describing uncertainties such as contract loss, backlog conversion, pricing pressure, international operations, regulatory compliance, and information systems risks. Quarterly reports on Form 10-Q provide interim financial updates and additional context on operating performance in the clinical research and development services business.
The company also files current reports on Form 8-K to disclose specific events. For example, Medpace has used Form 8-K to furnish earnings press releases under Item 2.02 and to describe amendments to its unsecured credit facility under Item 1.01, including changes to the aggregate principal amount available under its line of credit. These filings give detail on financing arrangements and other material developments beyond the headline numbers in press releases.
On Stock Titan, Medpace filings are paired with AI-powered summaries that highlight key points from lengthy documents, such as major changes in revenue and profitability, updates to guidance, or notable shifts in risk disclosures. Users can quickly scan 10-K and 10-Q reports, as well as 8-K items, while retaining the option to open the full SEC documents for deeper review. This page also surfaces information relevant to tracking management decisions, capital structure, and other regulatory matters that influence Medpace’s long-term profile as a global CRO.
Medpace Holdings, Inc. (MEDP) Form 144 summary: This notice reports a proposed sale of 38,013 common shares through UBS Financial Services on 08/27/2025. The filing lists an aggregate market value of $180,560,175 for the shares and shows 28,741,609 shares outstanding for the issuer. The shares were acquired by the seller on 02/15/2022 through an option exercise, with payment completed in cash on 03/01/2022. The filing also discloses a sale during the past three months: 48,487 shares sold on 07/28/2025 for $21,900,851. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Medpace Holdings, Inc. (MEDP) director Cornelius P. McCarthy III reported a sale of 1,662 shares of Medpace common stock on 08/19/2025 under Form 4. The sale is coded S and executed at a weighted average price of $465.04 per share (individual trade prices ranged from $465.022 to $465.355). After the reported transactions, the reporting person beneficially owned 10,197 shares, held directly. The Form 4 was signed by an attorney-in-fact, Stephen P. Ewald, on 08/21/2025. The filer is identified as a director of the company and the filing indicates compliance with Section 16 reporting obligations.
Medpace Holdings, Inc. (MEDP) filed a Form 144 reporting a proposed sale of 1,662 common shares. The shares are held at Fidelity Brokerage Services and are scheduled for an approximate sale date of 08/19/2025 on the NASDAQ. The aggregate market value is reported as $772,893.91 and the total number of common shares outstanding is 28,093,026, meaning the shares represent approximately 0.0059% of outstanding stock. The shares were acquired on 02/08/2024 by a stock option exercise from the issuer, paid in cash on the acquisition date. The filer reports no securities sold in the past three months for the account.
Medpace Holdings (MEDP) – Form 4 insider transaction
CEO, Chairman and 10% owner August J. Troendle sold 48,487 common shares on 28-Jul-2025 at a weighted-average price of $451.69 (range $450.00-$454.96), yielding roughly $21.9 million in proceeds. The sale was executed via a limit order during an open trading window.
After the sale, Troendle still controls 962,615 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC—about 5.7 million shares in total—so his overall influence remains substantial. No derivative transactions were reported.
The transaction trims his direct stake by ~5%, but does not materially alter insider ownership or governance dynamics.
Medpace Holdings, Inc. (MEDP) filed a Form 144 indicating an intended sale of 7,500 common shares through Fidelity Brokerage Services. The shares have an aggregate market value of $3.38 million, implying a per-share reference price of roughly $450 based on the data provided.
• Approximate sale date: 07/28/2025 on Nasdaq
• Shares outstanding: 28,093,026, so the proposed sale represents about 0.03 % of shares outstanding.
• Shares were acquired on 10/24/2023 via stock-option exercise paid in cash.
• No other sales have been reported by this filer in the past three months.
The signer certified no undisclosed material adverse information and affirmed compliance with Rule 10b5-1, if applicable. No further financial results or company-level disclosures accompany this notice.